認定特定非営利活動法人 特定非営利活動法人 North East Japan Study Group NEJSG

MENU

業績PERFORMANCE

論文

  1. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 Mar 20;27(9):1394-400. Epub 2009 Feb 17.

  2. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. Epub 2009 Jun 16.

  3. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010 Feb 1;126(3):651-5.

  4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8.

  5. Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 2011 Aug;6(8):1413-7.

  6. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. The Onlogist. 2012;17(6):863-70.

  7. Ebara T, Kawamura H, Kaminuma T, Okamoto M, Yoshida D, Okubo Y, Takahashi T, Sakaguchi H, Kobayashi K, Yoshitaka A, Nakano T, . Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma. J of Radiation Research 2012, vol./is. 53/2(288-94).

  8. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H; for the North-East Japan Study Group and the ALK Lung Cancer Study Group. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Oct 15;18(20):5682-5689. Epub 2012 Aug 20.

  9. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemmah A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012 Sep;7(9):1417-22.

  10. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T;North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. 2013 Jan:24(1):54-9.

  11. Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N. Interstitial Lung Disease Associated With Gefitinib in Japanese Patients With EGFR-mutated Non-Small-Cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405) Jpn J Clin Oncol. 2013 Jun;43(6):664-8.

  12. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014 Feb;9(2):189-94.

  13. Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y. Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respir Investig. 2014 Nov;52(6):339-47.

  14. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 2014 Nov;86(2):195-200.

  15. Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opin Pharmacother. 2015 Mar;16(4):465-72.

  16. Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol. 2015 May;26(5):888-94.

  17. Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer. 2015 May;88(2):181-6.

  18. Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol. 2015 Jul;45(7):670-6.

  19. Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K; North East Japan Study Group. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 2016 Sep;99:131-6.

  20. Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Invest New Drugs. 2017 Feb 1 Apr;35(2):227-234.

  21. Inoue Y, Shiihara J, Miyazawa H, Ohta H, Higo M, Nagai Y, Kobayashi K, Saijo Y, Tsuchida M, Nakayama M, Hagiwara K. A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer. PLoS One. 2017 Apr 27;12(4):e0176525.

  22. Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Updated Survival Outcomes of NEJ005/TCOG0902: A Randomised Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer With Sensitive EGFR Mutations. ESMO Open. 2018 Feb 23;3(2):e000313.

  23. Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients With Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients From NEJ023 Study. Oncologist. 2018 Oct;23(10):1210-1217.

  24. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib Plus Bevacizumab Versus Erlotinib Alone in Patients With EGFR-positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial. Lancet Oncol. 2019 May;20(5):625-635.

  25. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123.

  26. Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Clinical Outcomes of Second-Line Chemotherapy in Patients With Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients From the NEJ023 Study. Oncologist. 2020 Apr;25(4):e668-e674. doi: 10.1634/theoncologist.2019-0593. Epub 2019 Nov 26.

  27. Rintaro Noro , Kunihiko Kobayashi , Jiro Usuki , Makiko Yomota, Masaru Nishitsuji, Tsuneo Shimokawa, Masahiro Ando, Mitsunori Hino, Koichi Hagiwara, Akihiko Miyanaga, Masahiro Seike, Kaoru Kubota, Akihiko Gemma :; North East Japan Study group. Bevacizumab Plus Chemotherapy in Nonsquamous Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion Uncontrolled by Tube Drainage or Pleurodesis: A Phase II Study North East Japan Study Group Trial NEJ013B. Thorac Cancer. 2020 Jul;11(7):1876-1884.

  28. Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. eBioMedicine. 2020 Jul 3;57:102861. doi: 10.1016/j.ebiom.2020.102861. Online ahead of print.

  29. Kyoichi Kaira , Atsuto Mouri , Shingo Kato , Kenichi Yoshimura , Hiroshi Kagamu , Kunihiko Kobayashi A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non small cell lung cancer
    patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
    BMC Cancer . 2020 Oct 6;20(1):961. doi: 10.1186/s12885 020 07406 y.

  30. Hajime Asahina , Kentaro Tanaka , Satoshi Morita , Makoto Maemondo , Masahiro Seike , Isamu Okamoto , Satoshi Oizumi , Hiroshi Kagamu , Kazuhisa Takahashi , Toshiak i Kikuchi , Takeshi Isobe , Kenji Sugio , Kunihiko Kobayashi A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients W ith EGFR Mutated Advanced Non Small cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) Clin Lung Cancer . 2021 Mar;22(2):147 151. doi: 10.1016/j.cllc.2020.09.023. Epub 2020 Oct 16.

  31. Yukari Tsubata , Shun Shinomiya , Koji Inoue , Nobuhisa Ishikawa , Ryota Saito , Kazuhisa Nakashima , Katsuyuki Hotta , Akinobu Hamada , Fumio Nagashima , Yuichi Ando , Satoshi Morita , Kunihiko Kobayashi , Takeshi Isobe Protocol for a multi site, cluster randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non small cell lung cancer: the ENSUR E GA study BMC Geriatr . 2021 Jan 22;21(1):74. doi: 10.1186/s12877 021 02028 w.

  32. Yuji Minegishi , Ou Yamaguchi , Shunichi Sugawara , Sho ichi Kuyama , Satoshi Watanabe , Kazuhiro Usui , Masahide Mori , Osamu Hataji , Toshihiro Nukiwa , Satoshi Morita , Kunihiko Kobayashi , Akihiko Gemma A phase II study of first line afatinib for patients aged ≥75 years with EGFR mutation positive advanced non small cell lung cancer: North East Japan Study Group trial NEJ027 BMC Cancer . 2021 Mar 1;21(1):208. doi: 10.1186/s12885 021 07861 1.

  33. Kentaro Tanaka , Hajime Asahina , Junji Kishimoto , Yoshihiro Miyata , Takahiro Uchida , Kana Watanabe , Kosuke Hamai , Taishi Harada , Yukari Tsubata , Shunichi Sugawara , Kunihiko Kobayashi , Kenji Sugio , Satoshi Oizumi , Isamu Okamo to Osimertinib versus osimertinib plus chemotherapy for non small cell lung cancer with EGFR (T790M) associated resistance to initial EGFR inhibitor treatment: An open label, randomised phase 2 clinical trial Eur J Cancer . 2021 May;149:14 22. doi: 10.1016/j.ejca.2021.02.019. Epub 2021 Apr 1.

  34. Yosuke Kawashima , Tatsuro Fukuhara , Haruhiro Saito , Naoki Furuya , Kana Watanabe , Shunichi Sugawara ,Shunichiro Iwasawa , Yoshio Tsunezuka , Ou Yamaguchi , Morihito Okada , Kozo Yoshimori , Ichiro Nakachi , Masahiro Seike , Koichi Azuma , Futoshi Kurimoto , Yukari Tsubata , Yuka Fujita , Hiromi Nagashima , Gyo Asai , Satoshi Watanabe , Masaki Miyazaki , Koichi Hagiwara , Toshihiro Nukiwa , Satoshi Morita , Kunihiko Kobayashi , Makoto Maemondo Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR mutant non small cell lung cancer (NEJ026): overall survival analysis of an open label, randomised, multicentre, phase 3 trial Lancet Respir Med . 2022 Jan;10(1):72 82. doi: 10.1016/S2213 2600(21)00166 1. Epub 2021 Aug 26.

  35. Yukari Tsubata , Kana Watanabe , Ryota Saito , Atsushi Nakamura , Hiroshige Yoshioka , Mami Morita , Ryoichi Honda , Nobuhiro Kanaji , Satoshi Ohizumi , Daisuke Jingu , Taku Nakagawa , Kensuke Nakazawa , Atsuto Mouri ,Susumu Takeuch i , Naoki Furuya , Yuki Akazawa , Kiyotaka Miura , Eiki Ichihara , Makoto Maemondo , Satoshi Morita ,Kunihiko Kobayashi , Takeshi Isobe Osimertinib in poor performance status patients with T790M positive advanced non small cell lung cancer after progression of first and second generation EGFR TKI treatments (NEJ032B) Int J Clin Oncol . 2022 Jan;27(1):112 120. doi: 10.1007/s10147 021 02043 2. Epub 2021 Oct 13.

その他投稿

※無断転載・複製を禁ず

受賞

  • 文部科学大臣賞 (萩原 弘一、長井 良昭、小林 国彦、宮澤 仁志、田中 知明)
  • 日本肺癌学会 篠井・河合賞 (井上 彰)
  • 日本呼吸器学会 奨励賞 (井上 彰)
  • 東北医学会 奨学賞A (井上 彰)
  • International Research Promotion Council (IRPC) World Scientists Forum International Award (小林 国彦)
  • 日本学術振興会賞 (井上 彰)
  • 後藤喜代子・ポールブルダリ科学賞(前門戸 任)
  • Annals of Oncology 賞(井上 彰)